Nanoparticle based-immunotherapy against allergy

Immunotherapy. 2014;6(7):885-97. doi: 10.2217/imt.14.63.

Abstract

Allergic diseases are one of the most prevalent diseases, reaching epidemic proportions in developed countries. An allergic reaction occurs after contact with an environmental protein, such as inhalants allergens (pollen, animal dander, house dust mites), or food proteins. This response is known as part of the type 2 immunity that is counterbalanced by Type 1 immunity and Tregs. Widely used allergen-specific immunotherapy (IT) is a long term treatment to induce such switch from Th2 to Th1 response. However, conventional IT requires multiple allergen injections over a long period of time and is not free of risk of producing allergic reactions. As a consequence, new safer and faster immunotherapeutic methods are required. This review deals with allergen IT using nanoparticles as allergen delivery system that will allow a different way of administration, reduce dose and diminish allergen exposure to IgE bound to mast cells or basophils.

Keywords: adjuvant; allergy; anaphylaxis; immunotherapy; nanoparticle.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Allergens / immunology
  • Allergens / therapeutic use*
  • Basophils / immunology
  • Basophils / pathology
  • Humans
  • Hypersensitivity / immunology
  • Hypersensitivity / pathology
  • Hypersensitivity / therapy*
  • Immunoglobulin E / immunology
  • Immunotherapy / methods*
  • Mast Cells / immunology
  • Mast Cells / pathology
  • Nanoparticles*
  • Th1 Cells / immunology
  • Th1 Cells / pathology
  • Th2 Cells / immunology
  • Th2 Cells / pathology

Substances

  • Allergens
  • Immunoglobulin E